Sunosi is an oral phenylalanine-derived selective dopamine and norepinephrine reuptake inhibitor (DNRI). Norepinephrine inhibits rapid eye movement sleep and promotes wakefulness. Dopamine plays a role in areas of the brain responsible for sleep regulation. Sunosi is indicated for the improvement in wakefulness in adult patients with excessive sleepiness associated with narcolepsy or obstructive sleep apnea.

If you have a Hayes login, click here to view the full report on the Knowledge Center.